We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cofactor Genomics, FLX Bio Partner

Cofactor Genomics, FLX Bio Partner content piece image

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Cofactor Genomics, FLX Bio Partner"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Cofactor Genomics has announced that they have partnered with FLX Bio to develop a novel RNA-based IO analysis platform. The platform, called Cofactor Paragon, will use Cofactor’s RNA signature technology, Sigmund, to analyze the immune response of cancer patients. Cofactor Paragon is designed to replace flow-cytometry, genomic sequencing, and expression profiling, all of which are currently used in various combinations to better understand patients’ immune responses to therapeutic intervention, such as those being developed by FLX Bio.

Cofactor Paragon extracts all the necessary data from a single RNA extraction. Under the terms of the agreement, FLX Bio will apply their unique IO insights and expertise to provide purified immune cells, validation samples, and tumor samples while Cofactor will apply its RNA assay development and RNA signature technology. The two companies will jointly develop aspects of the IO analysis platform.

In return, FLX will have access to data generated during platform development and a license to use Cofactor’s Paragon for R&D purposes to support their drug discovery efforts. Following positive feedback from alpha users, Cofactor is actively recruiting both academic and pharma early access beta users.
“The response we’ve had from pharma clients interested in this assay has been astounding. The decision to integrate multiple IO analyses into a single platform, while challenging, has proved to be exactly what the field needs,” stated Jarret Glasscock, Cofactor’s CEO. "Clinical researchers are most excited about the potential to replace flow cytometry, allowing access to characterize more samples, including FFPE archives.”
Brian Wong, CEO of FLX Bio said, “The field of IO is in need of cost-effective and efficient assays to accurately measure the highly complex immune response in the tumor microenvironment. Cofactor’s Paragon solution has the potential to give us a quantitative look at this immune environment more efficiently than is possible with other technologies. We expect Paragon to accelerate our efforts to bring new cancer immunotherapies through to the clinic and to patients.”

Source: Story from FLX Bio. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.